PD−L1 immunostaining: what pathologists need to know

Clinical efficacy and safety of anti-PD-1/PD-L1 inhibitors for the treatment of advanced or metastatic cancer: a systematic review and meta-analysis

(2020) Leitao Sun et al.   Scientific Reports

Cytology cell blocks from malignant pleural effusion are good candidates for PD-L1 detection in advanced NSCLC compared with matched histology samples

(2020) Yinying Zou et al.   BMC CANCER

Immune checkpoint signaling and cancer immunotherapy

(2020) Xing He et al.   CELL RESEARCH

Systematic review: Soluble immunological biomarkers in advanced non-small-cell lung cancer (NSCLC)

(2020) Finn Mildner et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Implementation of PD-L1 22C3 IHC pharmDxTM in Cell Block Preparations of Lung Cancer: Concordance with Surgical Resections and Technical Validation of CytoLyt® Prefixation

(2020) Si Kei Lou et al.   ACTA CYTOLOGICA

Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy

(2020) Yun Liang et al.   Diagnostic Pathology

Comparison of three PD-L1 immunohistochemical assays in head and neck squamous cell carcinoma (HNSCC)

(2020) Emma J. de Ruiter et al.   MODERN PATHOLOGY

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

(2020) Jin-Yu Sun et al.   Biomarker Research

Immunohistochemical detection of PD-L1 among diverse human neoplasms in a reference laboratory: observations based upon 62,896 cases

(2019) Dennis P. O’Malley et al.   MODERN PATHOLOGY

Variation of Programmed Death Ligand 1 Expression After Platinum-based Neoadjuvant Chemotherapy in Lung Cancer

(2019) Lei Guo et al.   JOURNAL OF IMMUNOTHERAPY

Existing and Emerging Biomarkers for Immune Checkpoint Immunotherapy in Solid Tumors

(2019) Sanjeevani Arora et al.   ADVANCES IN THERAPY

Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

(2019) Akintunde Akinleye et al.   Journal of Hematology & Oncology

Tumor neoantigens: from basic research to clinical applications

(2019) Tao Jiang et al.   Journal of Hematology & Oncology

Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis

(2019) Moritz Widmaier et al.   MODERN PATHOLOGY

The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors

(2019) Andrew A. Davis et al.   Journal for ImmunoTherapy of Cancer

Structure and Optimization of Checkpoint Inhibitors

(2019) Sarah L. Picardo et al.   Cancers

PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics

(2018) Margarita Udall et al.   Diagnostic Pathology

Digital image analysis improves precision of PD-L1 scoring in cutaneous melanoma

(2018) Viktor H Koelzer et al.   HISTOPATHOLOGY

Regulation and Function of the PD-L1 Checkpoint

(2018) Chong Sun et al.   IMMUNITY

Fundamental Mechanisms of Immune Checkpoint Blockade Therapy

(2018) Spencer C. Wei et al.   Cancer Discovery

PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer

(2017) Katerina Ancevski Hunter et al.   Molecular Diagnosis & Therapy

Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma

(2017) Edwin R. Parra et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

What does PD-L1 positive or negative mean?

(2016) Antoni Ribas et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Human Tumor Antigens and Cancer Immunotherapy

(2015) Nathalie Vigneron   Biomed Research International